Inhaled bronchodilators (alone or in combination) are the cornerstone of treatment for
symptomatic patients with COPD, either as initial/first-line treatment or for second …

Background Randomized controlled trials (RCTs) indicate that long-acting bronchodilator
combinations, such as β2-agonist (LABA)/muscarinic antagonist (LAMA), have favorable …

Long-acting muscarinic antagonist (LAMA) or long-acting β2-agonist (LABA) bronchodilators
and their combination are recommended for the maintenance treatment of chronic …

Rationale: There is uncertainty on the optimal first-line therapy for symptomatic chronic
obstructive pulmonary disease (COPD). Long-acting β2-receptor agonists (LABAs) and long …

Inhaled bronchodilator therapy with long-acting muscarinic antagonists (LAMAs) and long-
acting β2-agonists (LABAs) in combination is currently the mainstay of treatment for chronic …

In this guideline update, we highlight important and new findings related to pharmacological
therapy of chronic obstructive pulmonary disease (COPD) that should change clinical …

Introduction Several dual bronchodilator fixed‐dose inhaler medications were recently
approved for the treatment of chronic obstructive pulmonary disease (COPD). These …

ABBREVIATIONS: AE= adverse event; ASM= airway smooth muscle; CV= cardiovascular;
FDC= fixed-dose combination; GOLD= Global Initiative for Chronic Obstructive Lung …

Bronchodilators provide improvements in lung function and reductions in symptoms and
exacerbations, and are the mainstay of pharmacological management of chronic obstructive …

Background Inhaled bronchodilators including long-acting beta-agonist (LABA) and long-
acting muscarinic antagonist (LAMA) play a central role in the treatment of stable chronic …